Kairos Pharma, LTD. (KAPA) SEC Filings — 2025

Filings

• Kairos Pharma's Net Loss Widens to $4.08M Amid Soaring R&D Costs — 10-Q · Nov 14, 2025
• Kairos Pharma Announces Board & Executive Changes — 8-K · Oct 15, 2025
• Kairos Pharma Enters Material Definitive Agreement — 8-K · Oct 7, 2025
• Kairos Pharma Files 8-K Report — 8-K · Sep 18, 2025
• Kairos Pharma Files 8-K — 8-K · Sep 11, 2025
• Kairos Pharma Files 8-K — 8-K · Sep 3, 2025
• Kairos Pharma's Losses Mount Amid R&D Surge, Secures Fresh Capital — 10-Q · Aug 12, 2025
• Kairos Pharma Files 10-K/A Amendment for FY24 Report — 10-K/A · Jul 28, 2025
• Kairos Pharma Files 8-K: Other Events & Financials — 8-K · Jul 15, 2025
• Kairos Pharma Files 8-K: Material Agreement & Shareholder Vote — 8-K · Jun 12, 2025
• Kairos Pharma Files 8-K — 8-K · Jun 3, 2025
• Kairos Pharma Files Q1 2025 10-Q — 10-Q · May 14, 2025
• Kairos Pharma Files 2025 Proxy Statement — DEF 14A · May 1, 2025
• Kairos Pharma Files 2024 Annual Report Amendment — 10-K/A · Apr 29, 2025
• Kairos Pharma Appoints Marcum LLP as New Auditor — 8-K · Apr 28, 2025
• Kairos Pharma Files 8-K — 8-K · Apr 24, 2025
• Kairos Pharma Files for Public Offering — S-1 · Apr 22, 2025
• Kairos Pharma Files 2024 10-K — 10-K · Apr 15, 2025
• Kairos Pharma Files 8-K: Other Events & Exhibits — 8-K · Mar 20, 2025
• Kairos Pharma Files 8-K Report — 8-K · Feb 26, 2025
• Kairos Pharma Files 8-K: Other Events & Financials — 8-K · Feb 6, 2025
• Kairos Pharma Files for IPO — S-1 · Jan 29, 2025
• Kairos Pharma Enters Material Agreement, Reports Equity Sales — 8-K · Jan 17, 2025
• Kairos Pharma Files 8-K on Agreements and Equity Sales — 8-K · Jan 14, 2025